|
WO2020222573A1
|
|
Ligand-drug conjugate including linker having tris structure
|
|
KR20200127891A
|
|
Ligand-drug conjugate comprising linker having tris structure
|
|
KR20210028556A
|
|
Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
|
|
WO2020180121A1
|
|
Antibody-drug conjugates including antibody against human dlk1, and use thereof
|
|
KR20200107837A
|
|
Antibody-drug conjugate comprising antibody binding to antibody against human DLK1 and its use
|
|
US2020172542A1
|
|
Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
|
|
WO2020141923A2
|
|
Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
|
|
KR20200084802A
|
|
Pyrrolobenzodiazepine dimer compounds with improved safety and its use
|
|
KR20210028544A
|
|
Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
|
|
AU2019266406A1
|
|
Compositions and methods related to anti-CD19 antibody drug conjugates
|
|
WO2019145784A2
|
|
Combination therapies for multi-drug resistant pathogens
|
|
WO2019035649A1
|
|
Antibody-drug conjugates including antibody against egfrviii
|
|
KR20190018400A
|
|
Antibody-drug conjugate comprising antibody binding to epidermal growth factor receptor variant III
|
|
WO2018182341A1
|
|
Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
|
|
KR20180110645A
|
|
Pyrrolobenzodiazepine dimer prodrug and its ligand-linker conjugate compound
|
|
KR101798840B1
|
|
Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same
|
|
KR20180093307A
|
|
Preparing Method of 4,5-diamino substituted pyrimidine derivatives and Novel Compound for Preparing thereof
|
|
EP3380124A1
|
|
Conjugates comprising self-immolative groups and methods related thereto
|
|
US2019151465A1
|
|
Antibody-drug conjugates comprising branched linkers and methods related thereto
|
|
EP3380125A1
|
|
Conjugates comprising peptide groups and methods related thereto
|
